Open Access iconOpen Access

ARTICLE

Pharmacotherapeutics and molecular docking studies of alpha-synuclein modulators as promising therapeutics for Parkinson’s disease

RAHAT ALI1, AFTAB ALAM2, SATYENDRA K. RAJPUT3, RAZI AHMAD4,*

1 Department of Medical Elementology and Toxicology, Jamia Hamdard, New Delhi, 110062, India
2 Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, 110025, India
3 Department of Pharmaceutical Sciences, Gurukul Kangri University, Uttarakhand, 249404, India
4 Department of Pharmacology HIMSR, Jamia Hamdard, New Delhi, 110062, India

* Corresponding Author: RAZI AHMAD. Email: email

BIOCELL 2022, 46(12), 2681-2694. https://doi.org/10.32604/biocell.2022.021224

Abstract

Parkinson’s disease (PD) is an age-related neurodegenerative ailment that affects dopamine-producing neurons in a specific area of the brain called the substantia nigra of the ventral midbrain. It is clinically characterized by movement disorder and marked with unusual synaptic protein alpha-synuclein accumulation in the brain. To date, only a few Food and Drug Administration (FDA) approved drugs are available on the market for the treatment of PD. Nonetheless, these drugs show parasympathomimetic related adverse events and remarkably higher toxicity; hence, it is important to find more efficacious molecules to treat PD. In our study, We chosen 22 natural compounds as inhibitors that potentially block the alpha-synuclein clump—the pathological hallmark of PD—and provide new avenues for its treatment. Most of these molecules exhibited good pharmacokinetic behaviors, making them decisively favorable drug candidates to cure PD. Molecular docking studies were performed to investigate the binding interactions between natural compounds and alpha-synuclein as anti-Parkinson drug targets. Among the examined compounds, curcumin and piperine emerged as promising phytochemicals with the highest binding affinity, key residual stable bindings and showed a good inhibitory features. Thus, the present study indicates that curcumin and piperine hold the potential to be developed as treatment options against PD. Experimental validations are needed for insights into their mechanism of action and potential clinical application.

Keywords


Supplementary Material

Supplementary Material File

Cite This Article

APA Style
ALI, R., ALAM, A., RAJPUT, S.K., AHMAD, R. (2022). Pharmacotherapeutics and molecular docking studies of alpha-synuclein modulators as promising therapeutics for parkinson’s disease. BIOCELL, 46(12), 2681-2694. https://doi.org/10.32604/biocell.2022.021224
Vancouver Style
ALI R, ALAM A, RAJPUT SK, AHMAD R. Pharmacotherapeutics and molecular docking studies of alpha-synuclein modulators as promising therapeutics for parkinson’s disease. BIOCELL . 2022;46(12):2681-2694 https://doi.org/10.32604/biocell.2022.021224
IEEE Style
R. ALI, A. ALAM, S.K. RAJPUT, and R. AHMAD "Pharmacotherapeutics and molecular docking studies of alpha-synuclein modulators as promising therapeutics for Parkinson’s disease," BIOCELL , vol. 46, no. 12, pp. 2681-2694. 2022. https://doi.org/10.32604/biocell.2022.021224



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 1139

    View

  • 757

    Download

  • 0

    Like

Share Link